An outbreak of Serratia marcescens on the neonatal unit: a tale of two clones

The Journal of Hospital Infection
M D DavidA P Fraise

Abstract

Serratia spp. are an important cause of hospital-acquired infections and outbreaks in high-risk settings. Twenty-one patients were infected or colonized over a nine-month period during 2001-2002 on a neonatal unit. Twenty-two isolates collected were examined for antibiotic susceptibility, beta-lactamase production and genotype. Random-amplified polymorphic DNA polymerase chain reaction and pulsed-field gel electrophoresis revealed that two clones were present. The first clone caused invasive clinical infection in four babies, and was subsequently replaced by a non-invasive clone that affected 14 babies. Phenotypically, the two strains also differed in their prodigiosin production; the first strain was non-pigmented whereas the second strain displayed pink-red pigmentation. Clinical features suggested a difference in their pathogenicity. No environmental source was found. The outbreak terminated following enhanced compliance with infection control measures and a change of antibiotic policy. Although S. marcescens continued to be isolated occasionally for another five months of follow-up, these were sporadic isolates with distinct molecular typing patterns.

References

Apr 19, 1979·The New England Journal of Medicine·V L Yu
Jul 1, 1976·The Journal of Pediatrics·W E StammH R de Quinones
Mar 1, 1986·The Journal of Hospital Infection·W R GransdenI Phillips
May 1, 1981·American Journal of Diseases of Children·D AnagnostakisN Matsaniotis
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Phillips, K Shannon
Jun 1, 1997·The Journal of Hospital Infection·M L van OgtropC P van Boven
Nov 22, 1997·Journal of Medical Microbiology·A HejaziF R Falkiner
Oct 28, 1998·American Journal of Obstetrics and Gynecology·C V TowersT Asrat
Oct 16, 1999·American Journal of Obstetrics and Gynecology·B M MercerB M Sibai
Feb 15, 2001·The Journal of Hospital Infection·B L JonesB Thakker
Feb 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Felix FleischChristian Ruef

❮ Previous
Next ❯

Citations

Oct 7, 2011·Clinical Microbiology Reviews·Steven D Mahlen
May 24, 2013·Journal of Clinical Microbiology·Andrea Karina MerkierDaniela Centrón
Dec 1, 2012·Journal of the Pediatric Infectious Diseases Society·Victoria A StatlerCharles R Woods
Jan 24, 2012·American Journal of Infection Control·Helena C MaltezouAlkiviadis Vatopoulos
Mar 30, 2010·International Journal of Medical Microbiology : IJMM·Yu-Tze HorngPo-Chi Soo
Sep 29, 2009·International Journal of Hygiene and Environmental Health·Alexander VoelzArne Simon
Aug 30, 2008·The Journal of Hospital Infection·A M Kh Al JaroushaA S Al Afifi
Jul 8, 2008·The Journal of Hospital Infection·D IvanovaA Bauernfeind
Aug 3, 2007·International Journal of Antimicrobial Agents·Miles Denton
Oct 21, 2006·The Journal of Hospital Infection·V Damjanovic, H K F van Saene
Sep 11, 2008·Acta Paediatrica·V RabierP Bétrémieux
Aug 12, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Ugur ArslanBülent Bozdogan
Nov 26, 2008·Journal of Chemotherapy·L E Espinosa de los MonterosV Valverde
Nov 26, 2009·Journal of Chemotherapy·A DessìV Fanos
Feb 23, 2019·International Journal of Environmental Research and Public Health·Maria Luisa CristinaAnna Maria Spagnolo
Jun 15, 2018·Journal of Clinical Microbiology·Christine MartineauCaroline Quach
Jul 17, 2020·Frontiers in Microbiology·Roumayne L FerreiraMaria-Cristina da Silva Pranchevicius
Jan 2, 2021·Open Medicine·Duško KljakićSaša Raičević
Mar 26, 2021·Microbial Pathogenesis·Martín A González-MontalvoAngel Andrade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Emmi SarvikiviHarri Saxén
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Lisa L MaragakisTrish M Perl
© 2021 Meta ULC. All rights reserved